ICMR-INDIAB-23 — Metabolic Obesity India

Source: The Lancet Regional Health – Southeast Asia (2024).

Key finding: 43.3% metabolically obese at normal BMI.

Part of GLP1Score's 20-study clinical evidence library — the peer-reviewed research powering our GLP-1 eligibility scoring engine.

Related Reading

Semaglutide in India — Complete Guide
Semaglutide Drug Monograph (dosing, contraindications)
Who Qualifies for Semaglutide in India
Endocrine Society of India Clinical Practice Guidelines for Obesity Management
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Higher-Dose Semaglutide (Up to 16 mg) for Type 2 Diabetes: A Phase 2 Dose-Ranging Study

Take the Free Eligibility Assessment → · Compare All 18+ Brands